methyl-3-(6-benzyloxynaphth-2-yl)-prop-2-enoate | 851124-28-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: methyl-3-(6-benzyloxynaphth-2-yl)-prop-2-enoate
• 英文别名: 3-(6-Benzyloxy-naphthalen-2-yl)-acrylic acid methyl ester；methyl (E)-3-(6-phenylmethoxynaphthalen-2-yl)prop-2-enoate
• CAS: 851124-28-2
• 化学式: C₂₁H₁₈O₃
• 分子量: 318.372
• InChiKey: TYTTWRFBYYJOFF-XYOKQWHBSA-N

物化性质

• 沸点：
  495.7±25.0 °C(Predicted)
• 密度：
  1.182±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl-3-(6-benzyloxynaphth-2-yl)-prop-2-enoate 在 palladium 10% on activated carbon 氢气 作用下， 以 乙酸乙酯 为溶剂， 20.0 ℃ 、413.69 kPa 条件下， 反应 24.0h， 以90%的产率得到methyl-3-(6-hydroxy-1,2,3,4-tetrahydronaphth-2-yl)propionate
  参考文献：
  名称：

  [EN] NOVEL COMPOUNDS AND THEIR USE AS ANTIDIABETIC AND HYPOLIPIDEMIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  [FR] NOUVEAUX COMPOSES ET LEUR UTILISATION EN MEDECINE, LEUR PROCEDE DE PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT

  摘要：

  公开号：

  WO2005040102A3
• 作为产物：
  描述：

  2-萘甲醛,6-(苯基甲氧基)- 、 三甲基膦酰基乙酸酯 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 17.0h， 以95%的产率得到methyl-3-(6-benzyloxynaphth-2-yl)-prop-2-enoate
  参考文献：
  名称：

  [EN] NOVEL COMPOUNDS AND THEIR USE AS ANTIDIABETIC AND HYPOLIPIDEMIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  [FR] NOUVEAUX COMPOSES ET LEUR UTILISATION EN MEDECINE, LEUR PROCEDE DE PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT

  摘要：

  公开号：

  WO2005040102A3

文献信息

• Substituted azole derivatives as therapeutic agents
  申请人：——

  公开号：US20040192743A1

  公开（公告）日：2004-09-30

  This invention provides azoles which may be useful as inhibitors of protein tyrosine phosphatases (PTPases). The present invention provides compounds of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds and their use in treating human or animal disorders. The compounds of the invention may be useful as inhibitors of protein tyrosine phosphatases and thus can be useful for the management, treatment, control and adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes, Type II diabetes.

  这项发明提供了一些可能作为蛋白酪氨酸磷酸酶（PTPases）抑制剂有用的唑类化合物。本发明提供了式（I）的化合物，它们的制备方法，包含这些化合物的制药组合物以及它们在治疗人类或动物疾病中的应用。本发明的化合物可能作为蛋白酪氨酸磷酸酶的抑制剂有用，因此可用于管理、治疗、控制和辅助治疗由PTPase活性介导的疾病，如1型糖尿病、2型糖尿病等。
• Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them
  申请人：Debnath Bhunia

  公开号：US20070093476A1

  公开（公告）日：2007-04-26

  The present invention relates to novel compounds of formula (I) and their pharmaceutically acceptable salts, wherein ring “Ar 1 ” represents a monocyclic or polycyclic aromatic or partially saturated aromatic polycyclic, which may optionally contain up to 3 heteroatoms selected from N, S or O. The said monocyclic or polycyclic ring may be unsubstituted or have up to 4 substituents which may be identical or different; m and n independently represents an integer from 0 to 6; A represents O, S or bond; Y is selected from (CH 2 ) p′ (CH 2 ) p B(CH 2 ) q′ (CH 2 ) r B(CH 2 ) p D(CH 2 ) p′ where p, q and r each independently represents an integer from 0 to 6; B and D independently represents S, O, NR 4 or a bond, with a proviso that when B and D represents hereto atom p is not zero; R 4 represents hydrogen, alkyl, alkenyl, —S(O) 2 —R 8 or —C(O)R 8 where R 8 is alkyl, alkoxy; R 5 and R 6 independently represents hydrogen, alkyl, cycloalkyl or alkoxy; R 5 and R 6 together may form 3-8 membered cyclic ring which may optionally contains one or two hereto atoms selected from O, S or N; R 7 represents hydrogen, optionally substituted groups selected form alkyl, cycloalkyl, alkenyl or alkynyl. The present invention also relates to a process for preparation of compounds of formula (I), to pharmaceutical compositions containing compounds of formula (I) and their use in particular as antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic agents.

  本发明涉及公式（I）的新化合物及其药学上可接受的盐，其中环“Ar1”表示单环或多环芳香或部分饱和芳香多环，可选含有最多3个选自N、S或O的杂原子。所述的单环或多环环可以未取代或具有最多4个相同或不同的取代基；m和n分别表示0到6的整数；A表示O、S或键；Y选自（CH2）p′（CH2）pB（CH2）q′（CH2）rB（CH2）pD（CH2）p′，其中p、q和r各自独立地表示0到6的整数；B和D分别表示S、O、NR4或键，条件是当B和D表示杂原子时，p不为零；R4表示氢、烷基、烯基、—S（O）2—R8或—C（O）R8，其中R8为烷基、烷氧基；R5和R6各自独立地表示氢、烷基、环烷基或烷氧基；R5和R6可以一起形成3-8成员环，该环可以选择性地包含选自O、S或N的一个或两个杂原子；R7表示氢、可选地从烷基、环烷基、烯基或炔基中选择的取代基。本发明还涉及公式（I）化合物的制备方法，含有公式（I）化合物的制药组合物以及其作为抗糖尿病、降脂、抗肥胖和降胆固醇药物的应用。
• Substituted Azole Derivatives as Therapeutic Agents
  申请人：Mjalli Adnan M. M.

  公开号：US20110077399A1

  公开（公告）日：2011-03-31

  This invention provides azoles which may be useful as inhibitors of protein tyrosine phosphatases (PTPases). The present invention provides compounds of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds and their use in treating human or animal disorders. The compounds of the invention may be useful as inhibitors of protein tyrosine phosphatases and thus can be useful for the management, treatment, control and adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes, Type II diabetes.

  本发明提供了一些可能用作蛋白酪氨酸磷酸酶（PTPases）抑制剂的唑类化合物。本发明提供了式（I）的化合物，它们的制备方法，包含这些化合物的药物组合物以及它们在治疗人类或动物疾病方面的用途。本发明的化合物可能有用作蛋白酪氨酸磷酸酶的抑制剂，因此可以用于管理、治疗、控制和辅助治疗由PTPase活性介导的疾病，例如1型糖尿病、2型糖尿病。
• SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS
  申请人：Transtech Pharma, Inc.

  公开号：EP1594847A2

  公开（公告）日：2005-11-16
• [EN] SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS<br/>[FR] UTILISATION DE DERIVES D'AZOLES SUBSTITUES EN TANT QU'AGENTS THERAPEUTIQUES
  申请人：TRANSTECH PHARMA INC

  公开号：WO2004071447A2

  公开（公告）日：2004-08-26

  This invention provides azoles which may be useful as inhibitors of protein tyrosine phosphatases (PTPases). The present invention provides compounds of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds and their use in treating human or animal disorders. The compounds of the invention may be useful as inhibitors of protein tyrosine phosphatases and thus can be useful for the management, treatment, control and adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes, Type II diabetes.